RxDoctor Payments Data

Jerry Thomas, MD

Family Medicine · Cape Coral, FLNPI 1891777090

Payments from drug & device makers

$1,070in general payments, 2019–2025

Across 51 payments — averaging $20.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$234
  • Amgen$175
  • Pfizer$124
  • AbbVie$84
  • Merck$73
  • Abbott$70
  • plus $310 from 10 others

What the payments were for

  • Food & beverage$1,06399%
  • Education$71%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,070 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$500,281
Medicare patients
759
Services billed
16,403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban183$231,452
TrulicityDulaglutide127$142,527
XareltoRivaroxaban88$101,737
MounjaroTirzepatide86$100,141
JanuviaSitagliptin Phosphate66$79,898
JardianceEmpagliflozin48$65,017
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$29,626
LinzessLinaclotide30$29,616
JanumetSitagliptin Phos/Metformin Hcl18$29,547
Breo ElliptaFluticasone/Vilanterol38$27,575
Lantus SolostarInsulin Glargine,hum.Rec.Anlog144$27,109
OzempicSemaglutide20$22,432
Humalog Kwikpen U-100Insulin Lispro25$13,262
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$13,066
SymbicortBudesonide/Formoterol Fumarate14$10,174

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$17$242,668213 claims
PfizerEliquis$124$231,452183 claims
MerckJanuvia, Janumet$73$109,44584 claims
Johnson & JohnsonXarelto$15$101,73788 claims
GSKTrelegy Ellipta, Breo Ellipta$27$57,20170 claims
AbbVieLinzess$84$29,61630 claims
Novo NordiskOzempic$234$22,43220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Cape Coral

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →